tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveitis D014605 14 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Uremia D014511 33 associated lipids
Ulcer D014456 16 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Tremor D014202 15 associated lipids
Translocation, Genetic D014178 20 associated lipids
Toxocariasis D014120 3 associated lipids
Tongue Diseases D014060 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Tinea D014005 5 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombosis D013927 49 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thinness D013851 11 associated lipids
Testicular Diseases D013733 15 associated lipids
Telangiectasis D013684 2 associated lipids
Tachycardia D013610 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Sclerosis D012598 5 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Osteosarcoma D012516 50 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Sarcoidosis D012507 13 associated lipids
Rupture D012421 2 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rosacea D012393 13 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Retinoblastoma D012175 12 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiration Disorders D012120 5 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Rectal Fistula D012003 2 associated lipids
Rectal Diseases D012002 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Pterygium D011625 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psoriasis D011565 47 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Pruritus Ani D011538 2 associated lipids
Prurigo D011536 4 associated lipids
Proteinuria D011507 30 associated lipids
Priapism D011317 1 associated lipids
Pregnancy Complications D011248 19 associated lipids
Precancerous Conditions D011230 48 associated lipids
Poxviridae Infections D011213 1 associated lipids
Postoperative Complications D011183 5 associated lipids
Polyneuropathies D011115 3 associated lipids
Pityriasis D010915 3 associated lipids
Pharyngitis D010612 2 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Periodontal Pocket D010514 9 associated lipids
Pericarditis D010493 6 associated lipids
Perceptual Disorders D010468 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pemphigus D010392 3 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Parotitis D010309 4 associated lipids
Paronychia D010304 3 associated lipids
Parkinson Disease D010300 53 associated lipids
Paresis D010291 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Pancytopenia D010198 6 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Pain D010146 64 associated lipids
Ovarian Cysts D010048 4 associated lipids
Osteoporosis D010024 12 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteomalacia D010018 5 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Christians U et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. 1991 Transplant. Proc. pmid:1721262
Beysens AJ et al. FK 506: monitoring in plasma or in whole blood? 1991 Transplant. Proc. pmid:1721263
Ullman KS et al. Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. 1991 Transplant. Proc. pmid:1721294
Sigal NH et al. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? 1991 Transplant. Proc. pmid:1721295
Cooper MH et al. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. 1991 Transplant. Proc. pmid:1721326
Didlake R and Grogan J Effect of FK 506 on rat leukocyte chemotaxis. 1991 Transplant. Proc. pmid:1721327
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. 1991 Transplant. Proc. pmid:1721358
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. 1991 Transplant. Proc. pmid:1721359
Armitage JM et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. 1991 Transplant. Proc. pmid:1703336
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Doi R et al. Mechanisms by which FK 506 affects exocrine pancreas in rats. 1991 Transplant. Proc. pmid:1721392
Cooper MH et al. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. 1991 Transplant. Proc. pmid:1721421
Yoshimi F et al. Canine total orthotopic small bowel transplantation under FK 506. 1991 Transplant. Proc. pmid:1721422
Goebl MG The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. 1991 Cell pmid:1706222
de Paulis A et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. 1991 J. Immunol. pmid:1706398
Sainsbury TS et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. 1991 Transplant. Proc. pmid:1721453
Fujino Y et al. FK 506 treatment of experimental autoimmune uveoretinitis in primates. 1991 Transplant. Proc. pmid:1721454
Hultsch T et al. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1712484
Miyahara H et al. Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. 1991 Clin. Immunol. Immunopathol. pmid:1712688
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Miyagawa S et al. Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. 1991 Transplant. Proc. pmid:1703687
Carroll PB et al. Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. 1991 Transplant. Proc. pmid:1703688
Flanagan WM et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. 1991 Nature pmid:1715516
Fujino Y et al. FK506 treatment of S-antigen induced uveitis in primates. 1991 Curr. Eye Res. pmid:1717199
McWhinnie DL and Morris PJ Combination drug therapies for immunosuppression in transplantation. 1991 Ann. Acad. Med. Singap. pmid:1724724
Pourtier-Manzanedo A et al. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. 1991 Anticancer Drugs pmid:1724925
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Matsukawa W et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. 1992 J. Lab. Clin. Med. pmid:1371298
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Ramamoorthy S et al. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. 1992 Pediatr. Res. pmid:1378960
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Reem GH Molecular mode of action of cyclosporin and FK506 in human thymocytes. 1992 J. Autoimmun. pmid:1380243
Bach JF Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. 1992 J. Autoimmun. pmid:1380245
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201